Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026

Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026

Bengaluru, Karnataka, India: March 28, 2026 : Biocon Limited (BSE: 532523; NSE: BIOCON) announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026, following approvals from the Nomination & Remuneration Committee and the Board of Directors. As the first CEO of the integrated Biocon, he will lead the…

Know More
Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide

Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide

BENGALURU, India, December 17, 2025: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), announced a new settlement and license agreement with Regeneron and Bayer for biosimilar Aflibercept (40mg/ml) in Europe and the rest of the world, which follows an earlier settlement covering the United…

Know More

Right Click is Disable for Security Purpose